Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
100%(9 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
9
82%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

9

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
2(18.2%)
Phase 2Efficacy & side effects
9(81.8%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(2)

Detailed Status

Completed9
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (18.2%)
Phase 29 (81.8%)

Trials by Status

withdrawn19%
terminated19%
completed982%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_2

A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

NCT03320941
completedphase_2

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

NCT03205150
completedphase_2

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

NCT02470403
completedphase_2

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

NCT03152591
completedphase_2

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

NCT03198767
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT03320941Phase 2

A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity

Completed
NCT03205150Phase 2

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

Completed
NCT02470403Phase 2

Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index

Completed
NCT03152591Phase 2

Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome

Completed
NCT03198767Phase 2

Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066

Completed
NCT03131479Phase 2

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Completed
NCT01407003Phase 1

Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) Assessment of LIK066 in Healthy Subjects and in Patients With Type 2 Diabetes Mellitus (T2DM)

Completed
NCT03100058Phase 2

A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults

Completed
NCT03152552Phase 2

A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Terminated
NCT01915849Phase 1

Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus

Completed
NCT01824264Phase 2

Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes

Withdrawn

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11